Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.
Study: T helper 2 cell–directed immunotherapy eliminates precancerous skin lesions. Image Credit: Me dia/Shutterstock.com Skin cancer rates are increasing globally, driving research into new ...